TLX ▼ -0.4% - Telix Pharmaceuticals Limited $TLX - Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway Telix Pharmaceuticals completed enrollment in its Phase 3 BiPASS study and reached alignment with the FDA on its new drug application pathway, yet shares declined 0.4% today. The milestone represents progress toward potential regulatory approval, though the modest stock reaction suggests investors may have already priced in expectations around the study or are awaiting efficacy data before reassessing the company's commercial prospects. 01-SEP-2026 06:18 PM ET